Drug class
Selective Cholesterol Absorption Inhibitor
A selective cholesterol absorption inhibitor is a lipid-lowering drug class, primarily represented by ezetimibe, that decreases circulating low-density lipoprotein cholesterol. Read more about Selective Cholesterol Absorption Inhibitor
38 drugs in this class 27 manufacturers
Drugs in Selective Cholesterol Absorption Inhibitor
EZETIMIBE
EZETIMIBE
EZETIMIBE-SIMVASTATIN (ezetimibe/simvastatin)
NEXLIZET (bempedoic acid/ezetimibe)
ZETIA (ezetimibe)
VYTORIN 10-10 (ezetimibe/simvastatin)
VYTORIN 10-20 (ezetimibe/simvastatin)
VYTORIN 10-40 (ezetimibe/simvastatin)
A selective cholesterol absorption inhibitor is a lipid-lowering drug class, primarily represented by ezetimibe, that decreases circulating low-density lipoprotein cholesterol.
Agents in this class act at the brush border of the small intestine by targeting the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein to selectively block the uptake of dietary and biliary cholesterol without impairing the absorption of triglycerides, fat-soluble vitamins, or bile acids.
They are utilized either as monotherapy or in combination with statins to manage primary hyperlipidemia, familial hypercholesterolemia, homozygous sitosterolemia, and to reduce cardiovascular risk in patients with atherosclerotic cardiovascular disease.
-
nih.gov
A selective cholesterol absorption inhibitor is a lipid-lowering drug class, primarily represented by ezetimibe, that decreases circulating low-density lipoprotein cholesterol Agents in this class act at the brush border of the small intestine by targeting the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein to selectively block the uptake of dietary and biliary cholesterol without impairing the absorption of triglycerides, fat-soluble vitamins, or bile acids They are utilized either as monot...
-
nih.gov
A selective cholesterol absorption inhibitor is a lipid-lowering drug class, primarily represented by ezetimibe, that decreases circulating low-density lipoprotein cholesterol They are utilized either as monotherapy or in combination with statins to manage primary hyperlipidemia, familial hypercholesterolemia, homozygous sitosterolemia, and to reduce cardiovascular risk in patients with atherosclerotic cardiovascular disease
-
nih.gov
Agents in this class act at the brush border of the small intestine by targeting the Niemann-Pick C1-Like 1 (NPC1L1) transporter protein to selectively block the uptake of dietary and biliary cholesterol without impairing the absorption of triglycerides, fat-soluble vitamins, or bile acids
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.